Evidence map›Paper›PMID 30740798›Full record

Trial reportTransfusion medicine (Oxford, England)2019

Transfusion service knowledge and immunohaematological practices related to sickle cell disease and thalassemia.

R M Fasano, J Branscomb, P A Lane, C D Josephson, A B Snyder, J R Eckman

Abstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Transfusion medicine (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Survey of Red Cell Transfusion Therapy and Immunohematology Services for Patients with Hemoglobinopathies in TürkiyeTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Red Cell Transfusions in the Genomics Era.Seminars in hematology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

R M FasanoCenter for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-8877-956X
J BranscombGeorgia Health Policy Center, Andrew Young School of Policy Studies, Georgia State University, Atlanta, Georgia, USA.
P A LaneAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics and Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
C D JosephsonCenter for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
A B SnyderGeorgia Health Policy Center, Andrew Young School of Policy Studies, Georgia State University, Atlanta, Georgia, USA.
J R EckmanDepartment of Hematology & Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.

Funding

REGISTRY AND EDUCATION FOR HEMOGLOBINOPATHIES AND HEMOVIGILANCE/TRANSFUSION THERAPYU58DD001138 · DD · GEORGIA STATE UNIVERSITY · PI SYNDER, ANGELA · 2014 to 2014
$470k
Centers for Disease Control and Prevention (CDC) 5NU58DD001138NCBDD CDC HHS U58 DD001138
6 · The paper itself

Abstract

objectivesTo assess current knowledge of National Heart, Lung and Blood Institutes (NHLBI) and Thalassemia International Federation (TIF) recommendations, blood banking practices and perceived challenges among transfusion services in the management of patients with haemoglobinopathies.

backgroundPrevious reports have demonstrated variations in transfusion practices for sickle cell disease (SCD) and thalassemia patients. Recently, NHLBI/TIF have provided transfusion recommendations for patients with haemoglobinopathies.

methodsA cross-sectional survey was conducted of transfusion services from the state of Georgia previously identified as having SCD/thalassemia populations. The survey assessed transfusion service practices in pre-transfusion testing and blood product selection; awareness/implementation of NHLBI/TIF transfusion-based recommendations and perceived challenges in transfusing haemoglobinopathy patients.

resultsResponses were received from 35 of 49 (71%) institutions. Only institutions indicating transfusing SCD or thalassemia patients (32) were included in analysis. Seventy-one percent of non-sickle cell treatment centres (SCTCs) and 20% of non-thalassemia treatment centres follow NHLBI and TIF recommendations to perform a red blood cell phenotype beyond ABO/Rh(D) and provide Rh and Kell prophylactically matched units for SCD and thalassemia patients, respectively. Forty percent of institutions (33% of non-SCTCs) employ RBC genotyping to evaluate the red cell phenotype for SCD patients. Over 77% of institutions do not utilise a reliable method to identify SCD patients prior to transfusion, such as a required question/answer field on type/screen or crossmatch orders.

conclusionMany healthcare systems' transfusion practices for haemoglobinopathy patients are discordant with NHLBI/TIF recommendations. Efforts are needed to increase awareness and implementation of current recommendations among all transfusion services seeing these patients.

Indexed as

Anemia, Sickle CellBlood Group AntigensBlood Grouping and CrossmatchingBlood TransfusionHealth Knowledge, Attitudes, PracticeThalassemiaBlood BanksCross-Sectional StudiesHumansPractice Guidelines as TopicBlood Group Antigensred cell transfusionsickle cell diseasethalassemia majortransfusion practices

Identifiers

PMID30740798
PMCPMC6767094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.